Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

verload and on development programs acquired through business development in 2013, including Lifitegrast. This growth was offset by reduced costs in relation to programs which have been discontinued following our pipeline prioritization review.

US GAAP R&D increased by $4.4 million, or 2%, as compared to Q3 2012.

Selling, General and Administrative ("SG&A")

% of % of product product 2013 sales 2012 sales $M $M SG&A (US GAAP) 441.1 37% 437.4 41% Intangible asset amortization (44.4) (50.0) Legal and litigation costs (8.5) (4.5) Depreciation (16.5) (14.2) SG&A (Non GAAP) 371.7 31% 368.7 35%

Non GAAP SG&A increased by $3.0 million, or 1%, a slower rate than the increase in product sales as we continue to focus on simplifying our business and delivering efficient growth.

US GAAP SG&A increased by $3.7 million, or 1%, as compared to Q3 2013.

For the nine months to September 30, 2013 Non GAAP SG&A decreased by $85.1 million, or 7%[1]; US GAAP SG&A decreased by $111.0 million, or 8%.

[1] For the full year guidance, refer to Outlook statement on page 3.


Gain on sale of product rights

For the three months to September 30, 2013 Shire recorded a gain on sale of product rights of $3.6 million (2012: $5.7 million) following re-measurement of the contingent consideration receivable from the divestment of DAYTRANA®.

Reorganization costs

For the three months to September 30, 2013 Shire recorded reorganization costs of $13.7 million (Q3 2012: $nil) primarily relating to the "One Shire" reorganization as we transition to a new operating structure.

Integration and acquisition costs

For the three months to September 30, 2013 Shire recorded integration and acquisition costs of $18.4 million primarily related to the change in fair value of contingent consideration a
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of the  ...  report to their offering.       (Logo: ... one of the fastest-growing segments in the chromatography ... in 2013, and expected to reach $2.0 billion ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... cells are undifferentiated biological cells that can differentiate into ... more stem cells. Stem cell therapy can be applied ... hematological system disease), nervous system diseases, damage or lesion ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... not the size of the eyespots on a male ... Instead, females are attracted to the "sparkle" created by ... at the center of eyespots, according to new research ... be published online June 29 in the Proceedings of ...
... between the two viruses could one day lead to ... researcher has discovered an unexpected link between the viruses ... an experimental strain of the human AIDS virus appear ... version of the disease as those immunized with the ...
... in a single gene can result in two ... to frequent or unusually severe infections, according to ... Nature Genetics. The discovery may lead to new ... A (IgA) deficiency and common variable immunodeficiency (CVID). ...
Cached Biology News:Female butterflies go for sparkle -- not size -- when choosing to mate 2Female butterflies go for sparkle -- not size -- when choosing to mate 3UF scientist finds unexpected link between cat and human AIDS viruses 2Agreement will speed research on microbicides for women 2Agreement will speed research on microbicides for women 3
Request Info...
R26.4C...
... x H): 17 3/4" x 8 ... slidesTime: Programmable 0 - 100 hoursControl: Programmable ... steps 40 user programmable protocols 3 operating ... Rapid temperature ramp-up from 37 - 95C ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: